Ask AI
See Activity Collection
ProCE Banner Activity

Assembly to Application: Frontline Response in Emergency Medicine: Best Practices for Prompt Recognition and Management of CAR T-Cell and Bispecific Antibody–Related Adverse Events

Slideset

These downloadable slides focus on the recognition and management of adverse events associated with CAR T-cell therapies and bispecific antibodies in patients with hematologic malignancies, with a focus on emergency department care. The slides review the clinical manifestations, timing, and grading of CRS and ICANS, including differentiation from infection, stroke, and other acute conditions. Evidence-based approaches to initial assessment, stabilization, treatment, and escalation of care are highlighted, along with product-specific monitoring requirements and delayed toxicities. Practical strategies for identifying treatment exposure, navigating evolving REMS requirements, and coordinating care across emergency medicine, oncology, and pharmacy teams are also addressed to support timely intervention and appropriate clinical decision-making.

Released: October 31, 2026

Continue Activity

Share

Faculty

Patrick C. Johnson

Patrick C. Johnson, MD

Clinical Director, Cellular Therapy Program, Hematologic Malignancies
Assistant Professor of Medicine
Harvard Medical School
Center for Lymphoma, MGB Cancer Institute
Boston, Massachusetts
Monica K. Wattana

Monica K. Wattana, MD

Associate Professor
Director of Education
Department of Emergency Medicine
UT MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity is intended for emergency medicine physicians, advanced practice providers, nurses, pharmacists, and other acute-care healthcare professionals in community and academic settings who may evaluate patients presenting with adverse events related to CAR T-cell therapy or bispecific antibody treatment.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify early CRS, ICANS, infection or neutropenic fever, stroke, delirium, and metabolic encephalopathy in patients with recent CAR T-cell therapy or bispecific antibody exposure

  • Apply grading criteria to facilitate appropriate first-hour stabilization, monitoring, and escalation steps

  • Initiate evidence-based ED management of suspected CRS or ICANS, including parallel infectious and neurologic workup, supportive care, antimicrobial therapy when indicated, cytokine-directed therapy or corticosteroids when appropriate, and ICU or transfer decisions

  • Use treatment-history tools, wallet cards, EHR documentation, CAR T REMS update knowledge, product-specific bispecific REMS/monitoring requirements, and SBAR handoff to improve coordination among care teams

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.